Oppenheimer on Aldeyra Therapeutics (ALDX): 'we are incrementally more optimistic about Reproxalap’s commercial potential in DED'
Tweet Send to a Friend
Oppenheimer analyst Justin Kim reiterated an Outperform rating and $12.00 price target on Aldeyra Therapeutics (NASDAQ: ALDX).The analyst comments "Following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
